Tel Aviv startup Cassidy Bio closed an $8 million seed round led by Ahren Innovation Capital to develop an AI platform that predicts optimal combinations of guide RNAs, editing enzymes and delivery modalities for therapeutic gene editing. Cassidy said it trained genomic foundation models on proprietary wet-lab and population-genomics data to tackle target selection, delivery, efficacy and specificity challenges. CEO Rom Kshuk framed the approach as a way to make genome editing development more predictable and scalable; Cassidy aims to reduce downstream clinical risk by improving design-stage confidence. Investors cited the need for computational-first tools to accelerate therapeutic editing programs across modalities and indications.